Skip to main content
. 2021 May 25;12(6):535. doi: 10.1038/s41419-021-03817-2

Fig. 2. Tet2 KO myoblasts display fusion defects in vitro.

Fig. 2

A Immunofluorescence staining of MyoD and EdU in myoblasts isolated from WT or Tet2 KO mice. Scale bars, 100 µm. B Quantification of the percentage of MyoD+ EdU+ myoblasts (n = 3). C Immunofluorescence staining of MyHC in differentiated myotubes. Scale bars, 200 µm. D Quantification of the fusion index in differentiated myotubes (n = 3). E Quantification of the average area in differentiated myotubes (n = 3). F Scheme of the second phase fusion assay. G Images of the second phase fusion assay results. Scale bars, 100 µm. H Quantification of the percentage of the dual labeled myotubes (n = 3). I Quantification of the fusion index of the dual labeled myotubes (n = 3). J Quantification of the average areas of dual labeled myotubes (n = 3). *p < 0.05, **p < 0.01, ***p < 0.001.